OTC · CIK 0001091596
AURX Nuo Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $1.30 on Oct 9, 2026, +69% from the 52-week low and -50% from the high.
In brief
Nuo Therapeutics, Inc. (AURX) has 26 SEC Form 4 filings on file from 6 insiders, the latest filed on Oct 6, 2026. In the last 90 days insiders made 1 open-market buy worth $9,539 and 0 open-market sells worth $0, net +$9,539.
3 open-market trades have been scored at AURX. The newest: David Emerson Jorden (CEO/CFO) bought $9,539 of stock on Aug 27, 2026, filed Aug 31, 2026, scored 28 (weak). The largest of the 3 shown: David Emerson Jorden (CEO/CFO) sold $300k on Nov 28, 2025, scored 39 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Nuo Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | David Emerson Jorden CEO/CFO buy | $9,539 8,773 shares | +0% | +39% from low-67% from high | |
| 39Weak | David Emerson Jorden CEO/CFO sell | $300k 200,000 shares | -9% | - | |
| 19Weak | Charles E Sheedy owner buy | $200k 133,333 shares | +1% | - |
Transactions
The newest 50 of 72 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Scott M. Pittman director, owner | AGrant or award Second Restated Warrant (right to buy)derivative | +4,500 | $1.50 | $6,750 | 4,500 | 7 d ago |
| Oct 6, 2026 | Scott M. Pittman director, owner | AGrant or award Prepayment Restated Warrant (right to buy)derivative | +458 | $1.50 | $687 | 458 | 7 d ago |
| Aug 27, 2026 | David Emerson Jorden CEO/CFO | POpen-market purchase Common Stock | +789 | $1.07 | $844 | 2,062,016 | 43 d ago |
| Aug 28, 2026 | David Emerson Jorden CEO/CFO | POpen-market purchase Common Stock | +7,984 | $1.09 | $8,695 | 2,070,000 | 43 d ago |
| Aug 27, 2026 | David Emerson Jorden CEO/CFO | AGrant or award Common Stock | +789 | $1.07 | $844 | 2,062,016 | Aug 28, 2026 |
| Aug 28, 2026 | David Emerson Jorden CEO/CFO | AGrant or award Common Stock | +7,984 | $1.09 | $8,695 | 2,070,000 | Aug 28, 2026 |
| Jun 29, 2026 | Paul Mintz director | AGrant or award Option to Purchase Common Stockderivative | +30,000 | $0.00 | $0 | 30,000 | Jul 2, 2026 |
| Jun 29, 2026 | Peter Clausen CSO/COO | AGrant or award Option to purchase common stockderivative | +65,000 | $0.00 | $0 | 65,000 | Jul 2, 2026 |
| Jun 30, 2026 | C Eric Winzer director | MOption exercise Common Stock | +40,000 | $1.00 | $40k | 212,654 | Jul 2, 2026 |
| Jun 30, 2026 | David Emerson Jorden CEO/CFO | MOption exercise Common Stock | +162,500 | $1.00 | $163k | 2,222,119 | Jul 2, 2026 |
| Jun 30, 2026 | Scott M. Pittman director, owner | MOption exercise Common Stock | +40,000 | $1.00 | $40k | 5,440,000 | Jul 2, 2026 |
| Jun 30, 2026 | David Emerson Jorden CEO/CFO | FTax withholding Common Stock | -160,892 | $1.01 | $163k | 2,061,227 | Jul 2, 2026 |
| Jun 30, 2026 | Scott M. Pittman director, owner | FTax withholding Common Stock | -39,604 | $1.01 | $40k | 5,400,396 | Jul 2, 2026 |
| Jun 30, 2026 | C Eric Winzer director | FTax withholding Common Stock | -39,604 | $1.01 | $40k | 173,050 | Jul 2, 2026 |
| Jun 30, 2026 | David Emerson Jorden CEO/CFO | MOption exercise Option to purchase common stockderivative | -162,500 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 30, 2026 | C Eric Winzer director | MOption exercise Option to purchase common stockderivative | -40,000 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 30, 2026 | Scott M. Pittman director, owner | MOption exercise Option to purchase common stockderivative | -40,000 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 29, 2026 | David Emerson Jorden CEO/CFO | AGrant or award Option to purchase common stockderivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jun 29, 2026 | C Eric Winzer director | AGrant or award Option to purchase common stockderivative | +30,000 | $0.00 | $0 | 30,000 | Jul 2, 2026 |
| Jun 29, 2026 | Scott M. Pittman director, owner | AGrant or award Option to purchase common stockderivative | +30,000 | $0.00 | $0 | 30,000 | Jul 2, 2026 |
| Jun 5, 2026 | David Emerson Jorden CEO/CFO | AGrant or award Common Stock | +13,245 | $1.10 | $15k | 2,085,000 | Jun 5, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Initial Warrant (right to buy)derivative | +30,050 | $1.50 | $45k | 30,050 | Jun 2, 2026 |
| May 29, 2026 | Scott M. Pittman director, owner | AGrant or award Interim Warrant (right to buy)derivative | +17,450 | $1.50 | $26k | 17,450 | Jun 2, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Second Warrant (right to buy)derivative | +36,750 | $1.50 | $55k | 0 | Jun 2, 2026 |
| May 29, 2026 | Scott M. Pittman director, owner | DDisposition to issuer Second Warrant (right to buy)derivative | -36,750 | $1.50 | $55k | 0 | Jun 2, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Prepayment Warrant (right to buy)derivative | +7,516 | $1.50 | $11k | 0 | Jun 2, 2026 |
| May 29, 2026 | Scott M. Pittman director, owner | DDisposition to issuer Prepayment Warrant (right to buy)derivative | -7,516 | $1.50 | $11k | 0 | Jun 2, 2026 |
| May 29, 2026 | Scott M. Pittman director, owner | AGrant or award Second Restated Warrant (right to buy)derivative | +17,500 | $1.50 | $26k | 0 | Jun 2, 2026 |
| May 29, 2026 | Scott M. Pittman director, owner | AGrant or award Prepayment Restated Warrant (right to buy)derivative | +7,333 | $1.50 | $11k | 0 | Jun 2, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Commitment Warrants (right to buy)derivative | +2,050 | $1.50 | $3,075 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Origination Initial Warrants (right to buy)derivative | +1,333 | $1.50 | $2,000 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Capital Initial Warrants (right to buy)derivative | +26,667 | $1.50 | $40k | 0 | Jan 26, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Origination Second Warrants (right to buy)derivative | +1,750 | $1.50 | $2,625 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Capital Second Warrants (right to buy)derivative | +35,000 | $1.50 | $53k | 0 | Jan 26, 2026 |
| Jan 23, 2026 | Scott M. Pittman director, owner | AGrant or award Prepayment Warrants (right to buy)derivative | +7,516 | $1.50 | $11k | 0 | Jan 26, 2026 |
| Jan 1, 2026 | David Emerson Jorden CEO/CFO | MOption exercise Common Stock | +125,000 | $0.40 | $50k | 2,071,755 | Jan 5, 2026 |
| Jan 1, 2026 | David Emerson Jorden CEO/CFO | FTax withholding Common Stock | -25,381 | $1.97 | $50k | 2,046,374 | Jan 5, 2026 |
| Dec 31, 2018 | David Emerson Jorden CEO/CFO | MOption exercise Option to purchase common stockderivative | -125,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Dec 17, 2025 | C Eric Winzer director | MOption exercise Common Stock | +68,750 | $0.40 | $28k | 186,404 | Dec 22, 2025 |
| Dec 17, 2025 | C Eric Winzer director | FTax withholding Common Stock | -13,750 | $2.00 | $28k | 172,654 | Dec 22, 2025 |
| Dec 31, 2025 | C Eric Winzer director | MOption exercise Option to purchase common stockderivative | -68,750 | $0.00 | $0 | 0 | Dec 22, 2025 |
| Dec 9, 2025 | Paul Mintz director | MOption exercise Common Stock | +50,000 | $0.40 | $20k | 117,385 | Dec 11, 2025 |
| Dec 9, 2025 | Paul Mintz director | MOption exercise Common Stock | +50,000 | $0.40 | $20k | 117,385 | Dec 11, 2025 |
| Dec 9, 2025 | Paul Mintz director | FTax withholding Common Stock | -9,091 | $2.20 | $20k | 108,294 | Dec 11, 2025 |
| Dec 9, 2025 | Paul Mintz director | FTax withholding Common Stock | -9,091 | $2.20 | $20k | 108,294 | Dec 11, 2025 |
| Dec 31, 2018 | Paul Mintz director | MOption exercise Option to purchase common stockderivative | -50,000 | $0.00 | $0 | 0 | Dec 11, 2025 |
| Dec 31, 2018 | Paul Mintz director | MOption exercise Option to purchase common stockderivative | -50,000 | $0.00 | $0 | 0 | Dec 11, 2025 |
| Nov 28, 2025 | David Emerson Jorden CEO/CFO | SOpen-market sale Common Stock | -200,000 | $1.50 | $300k | 1,946,755 | Dec 3, 2025 |
| Aug 1, 2025 | David Emerson Jorden CEO/CFO | MOption exercise Common Stock | +100,000 | $0.40 | $40k | 2,075,358 | Aug 4, 2025 |
| Jul 31, 2025 | Peter Clausen CSO/COO | MOption exercise Common Stock | +183,853 | $0.40 | $74k | 770,054 | Aug 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Peter ClausenCSO/COO
- David Emerson JordenCEO/CFO
- Paul Mintzdirector
- Scott M. Pittmandirector, owner
- Charles E Sheedyowner
- C Eric Winzerdirector
Questions about AURX
Answered from the filings on this page, as of the latest one.
Are insiders buying AURX?
As of Oct 6, 2026, SEC Form 4 filings show 1 open-market buy worth $9,539 by 1 insider and 0 open-market sells worth $0 by 0 insiders at Nuo Therapeutics, Inc. in the last 90 days, net +$9,539. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade AURX on the open market?
David Emerson Jorden (CEO/CFO) bought $9,539 of AURX on Aug 27, 2026 and filed the Form 4 on Aug 31, 2026. InsiderTell scored 28 (weak).
How many insiders file Form 4 at Nuo Therapeutics, Inc.?
6 people have filed a Form 4 at Nuo Therapeutics, Inc., among them Peter Clausen (CSO/COO), David Emerson Jorden (CEO/CFO), Paul Mintz (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.